Clinical Trial

A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-17.
Trial Details
NCT Number NCT07138846
Lead Sponsor Lepu Biopharma Co., Ltd.
Conditions Advanced Pancreatic Cancer
Enrollment 231 participants
Start Date 2027-01
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-15